clinical trial · NCT06161220
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
Impax Laboratories, LLC·phase1·completed·n = 35
Cardiac Repolarization in Healthy SubjectsCarbidopa capsuleMoxifloxacin Tablets, USPPlacebo
brief summary
The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
started
Oct 30, 2023
primary completion
Dec 3, 2023
completion
Dec 5, 2023
last updated
Mar 5, 2024
official title
A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol